VanEck Biotech ETF (NASDAQ:BBH) Trading Down 1.2% – Here’s What Happened

VanEck Biotech ETF (NASDAQ:BBH) dropped 1.2% during trading on Monday . The stock traded as low as $185.74 and last traded at $185.74. Approximately 3,478 shares were traded during trading, a decline of 21% from the average daily volume of 4,399 shares. The stock had previously closed at $188.00.

VanEck Biotech ETF Stock Performance

The company’s 50-day moving average price is $186.80 and its 200 day moving average price is $190.74.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BBH. Kestra Advisory Services LLC raised its holdings in VanEck Biotech ETF by 3.0% during the 1st quarter. Kestra Advisory Services LLC now owns 3,405 shares of the company’s stock valued at $640,000 after buying an additional 98 shares during the period. Janney Montgomery Scott LLC raised its holdings in VanEck Biotech ETF by 3.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,040 shares of the company’s stock valued at $572,000 after buying an additional 100 shares during the period. Wealthfront Advisers LLC raised its holdings in VanEck Biotech ETF by 2.3% during the 4th quarter. Wealthfront Advisers LLC now owns 5,513 shares of the company’s stock valued at $1,043,000 after buying an additional 122 shares during the period. Evelyn Partners Asset Management Ltd raised its holdings in VanEck Biotech ETF by 16.9% during the 4th quarter. Evelyn Partners Asset Management Ltd now owns 941 shares of the company’s stock valued at $178,000 after buying an additional 136 shares during the period. Finally, Empowered Funds LLC purchased a new stake in VanEck Biotech ETF during the 4th quarter valued at $38,000. 32.05% of the stock is currently owned by institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.